Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders

Journal of Mental Health Policy and Economics

Volumn 12, Issue 1, 2009, Pages 33-46

  Weaver, Marcia R ^a,g   Conover, Christopher J ^b   Proescholdbell, Rae Jean ^c   Arno, Peter S ^d   Ang, Alfonso ^e   Uldall, Karina K ^f   Ettner, Susan L ^e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Duke Center for Clinical Health Policy Research   (United States)

^c Center for Health Policy and Global Health Institute   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^g NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CASE MANAGEMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; EMERGENCY CARE; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTEGRATED HEALTH CARE SYSTEM; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL HEALTH SERVICE; MULTICENTER STUDY; OUTCOME ASSESSMENT; OUTPATIENT CARE; PRIMARY MEDICAL CARE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESIDENTIAL CARE; SELF REPORT; SF 6D; SHORT FORM 36; SUBSTANCE ABUSE;

ADOLESCENT; ADULT; CHRONIC DISEASE; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE, INTEGRATED; DIAGNOSIS, DUAL (PSYCHIATRY); FEMALE; HEALTH CARE COSTS; HIV INFECTIONS; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; MORTALITY; PATIENT COMPLIANCE; PRESCRIPTION FEES; QUALITY OF LIFE; SICKNESS IMPACT PROFILE; SUBSTANCE-RELATED DISORDERS; UNITED STATES; VIRAL LOAD; YOUNG ADULT;

EID: 64249125072     PISSN: 10914358     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Pence BW, Miller WC, Whetten K, Eron JJ, Gaynes BN. Prevalence of DSM-IV-defined mood, anxiety, and substance use disorders at an HIV clinic in southeastern United States. J Acquir Immune Defic Syndr 2006; 42: 298-306.
2. Lyketsos CG, Hanson A, Fishman M, McHugh PR, Treisman GJ. Screening for psychiatric morbidity in a medical outpatient clinic for HIV infection: the need for a psychiatric presence. International J Psychiatry Med 1994; 24: 103-113.
3. Tegger MK, Crane HM, Tapia KA, Uldall KK, Holt SE, Kitahata MM. The effect of mental illness, substance use, and treatment for depression on the initiation of highly active antiretroviral therapy among HIV-infected individuals. AIDS Patient Care STDs 2008; 22: 231-241.
4. Galvan F H, Burnam M A, Bing E G. Co-occurring psychiatric symptoms and drug dependence or heavy drinking among HIV-positive people. J Psychoactive Drugs 2003; 35: 153-160.
5. Whetten K, Reif SS, Napravnik S, Swartz MS, Thielman NM, Eron JJ, Lowe K, Soto T et al. Substance abuse and symptoms of mental illness among HIV-positive persons in the Southeast. South Med J 2005; 98: 9-14.
6. Douaihy AB, Jou RJ, Gorske T, Salloum IM. Triple diagnosis: Dual diagnosis and HIV disease, Part I. AIDS Read 2003; 13: 331-341.
7. Weaver MR, Conover C, Proescholdbell RJ, Arno PS, Ang A, Arno P, Ettner SL for the Cost Subcommittee of the HIV/AIDS Treatment Adherence, Health Outcomes and Cost Study. "Access to mental health and substance abuse care for people living with HIV/AIDS, chronic mental illness, and substance abuse disorders." J Acquir Immune Defic Syndr 2008; 47: 449-458.
8. Douaihy AB, Jou R J, Gorske T, Salloum IM. Triple diagnosis: dual diagnosis and HW disease, part 2. AIDS Read 2003; 13: 375-382.
9. Acuff C, Archambeault J, Greenberg B, Hoeltzel J, McDaniel J S, Meyer P, et al. Mental Health Care for People Living with or Affected by HIV/ AIDS: A Practical Guide. Rockville, MD: United States Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, National Mental Health Information Center, 1999. Available online at: http://mentalhealth.samhsa.gov/publications/allpubs/ KEN00-0081/default.asp Accessed on March 30, 2007.
10. Soto TA, Bell J, Pillen MB, et al. Literature on integrated HIV care: a review. AIDS Care 2004; 16: S43-S55.
11. Klinkenberg WD, Sacks S et al. Mental disorders and drug abuse in persons living with HIV/AIDS. AIDS Care 2004; 16: S22-S42.
12. Willenbring ML. Integrating care for patients with infectious, psychiatric, and substance use disorders: concepts and approaches. AIDS 2005; 19: S227-S237.
13. Blount E. Integrated primary care: organizing the evidence. Fam Syst Health 2003; 21: 121-133.
14. Winiarski MG, Beckett E, Salcedo J. Outcomes of an inner-city HIV mental health programme integrated with primary care and emphasizing cultural responsiveness. AIDS Care 2005; 17: 747-756.
15. Whetten K, Seif S, Ostermann J, Pence BW, Swartz M, Whetten R, Conover C, Bois S, Thielman N, Eron J. Improving health outcomes among individuals with HIV, mental illness, and substance use disorders in the Southeast. AIDS Care 2006; 18: S18-S26.
16. Freedberg KA, Losina E. Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, Craven DE, Zhang H, Kimmel AD, Goldie SJ. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344: 824-831.
17. Moore RD. Cost effectiveness of combination HIV therapy: 3 years later. Pharmacoeconomics 2000; 17: 325-330.
18. Freedberg KA, Hirschhorn LR, Schackman BR, Wolf LL, Martin LA, Weinstein MC, Goldin S, Paltiel AD, Katz C, Goldie SJ, Losina E. Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients. J Acquir Immune Defic Syndr 2006; 43: S113-S118.
19. Bozzette SA, Joyce G, McCaffrey DF, Leibowitz AA, Morton SC, Berry SH, Rastegar A, Timberlake D, Shapiro MF, Goldman DP for the HIV Cost and Services Utilization Consortium. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med 2001; 344: 817-823.
20. Gebo KA, Chaisson RE, Folkemer JG, Bartlett JG, Moore RD. Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS 1999; 13: 963-969.
21. Keiser P, Kvanti MB, Turner D, Reisch J, Smith JW, Nassar N, Gregg C, Skiest D. Protease inhibitor-based therapy is associated with decreased HIV-related health care costs in men treated at a Veterans Administration Hospital. J Acquir Immune Defic Syndr 1999; 20: 28-33.
22. Simon GE, Katzelnick DJ. Depression, use of medical services and cost-offset effects. J Psychosom Res 1997; 42: 333-334.
23. Armstrong MA, Midanik LT, Klatsky AL, Lazere A. Utilization of health services among patients referred to an alcohol treatment program. Sub Use Misuse 2001; 36: 1781-1793.
24. Holder HD. Cost benefits of substance abuse treatment: an overview of results from alcohol and drug use. J Ment Health Policy Econ 1998; 1: 23-29.
25. California Health Benefits Review Program (CHBRP). Analysis of Assembly Bill 1887: Health Care Coverage: Mental Health Services Oakland, CA: Report to California State Legislature, 2008. Available online at http://www.chbrp.org/documents/ab_1887._report.pdf Accessed on April 17, 2008.
26. Donohue JM, Pincus HA. Reducing the societal burden of depression: a review of economic costs, quality of care and effects of treatment. Pharmacoeconomics 2007; 25 (1): 7-24.
27. Mijch A, Burgess P, Judd F, Grech P, Komiti A, Hoy J, Lloyd JH. Gibbie, T, Street A. Increased health care utilization and increased antiretroviral use in HIV-infected individuals with mental health disorders. HIV Med 2006; 7: 205-212.
28. The HIV/AIDS Treatment Adherence, Health Outcomes, and Cost Study Group. The HIV/AIDS Treatment Adherence, Health Outcomes, and Cost Study: conceptual foundations and overview. AIDS Care 2004; 16: S6-S21.
29. First MB, Spitzer RL, Williams JBW, Gibbon M. Structured Clinical Interview for DSM-IV (SCID) Washington, DC: American Psychiatric Association, 1995.
30. Stoff, DM, Mitnick L, Kalichman S. Special Issue: HIV/AIDS Treatment Adherence, Health Outcomes and Cost Study. AIDS Care 2004; 16: S1-S5.
31. Palmer NB, Salcedo J, Miller A.L, Winiarski M, Arno P. Psychiatric and social barriers to HIV medication adherence in a triply-diagnosed methadone population. AIDS Patient Care STDs 2003; 17: 635-644.
32. Drummond MF, O'Brien B, Stoddart GL, Torrance, GW. Methods for the economic evaluation of health care programmes (2nd edition) Toronto: Oxford University Press, 1997.
33. Gold, MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in health and medicine New York: Oxford University Press, 1996.
34. World Health Organization. Generalized Cost-Effeciveness Analysis: A Guide Geneva: World Health Organization, 2003. Available online at: http://www.who.int/choice/en/ Accessed on April 14, 2008.
35. Rabeneck L, Menke T, Wray NP. How good are U.S. Studies of HIV Costs of Care? Med Care 1999; 37: 748-759
36. Medicare Payment Advisory Commission (MEDPAC). Report To Congress: Medicare Payment Policy Washington, DC: Medicare Payment Advisory Commission, 2004.
37. United States Department of Health and Human Services, Office of Inspector General. Cost Containment of Medicaid HIV/AIDS Drug Expenditures Washington, DC: Department of Health and Human Services, 2001.
38. Ware JE Jr, Sherbourne CD. The MOS 36-Item Short Form Health Survey (SF-36), I; conceptual framework and item selection. Med Care 1992; 30: 473-483.
39. Brazier J, Roberts J, Deverill M. The estimation of a preference-based single index measure for health from the SF-36. J Health Econ 2002; 21: 271-292.
40. Ware JE, Kolinski M, Keller SD. How to score the SF-12 physical and mental health summaries: a user's manual. Boston: The Health Institute, New England Medical Centre, 1995.
41. Ware JE Jr., Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34: 220-233.
42. Diehr P, Patrick DL, Spertus J, Kiefe C, McDonell M, Fihn SD. Transforming self-rated health and the SF-36 scales to include death and improve interpretability. Med Care 2001; 39: 670-680.
43. Anderson JP, Kaplan RM, Coons SJ, Schneiderman LJ. Comparison of the Qualify of Well-Being Scale and the SF-36 results among two samples of ill adults; AIDS and other illnesses. J Clin Epidemiol 1998; 51: 755-762.
44. Rubin DB. Multiple imputation for nonresponse in surveys. New York: Wiley, 1987.
45. Schafer JL. Analysis of incomplete multivariate data. New York: Chapman & Hall, 1997.
46. Manning, WG. The logged dependent variable, heteroskedasticity and the retransformation problem. J Health Econ 1998; 17: 283-295.
47. Mooney CZ, Duval RD. Bootstrapping: A nonparametric approach to statistical inference. Thousand Oaks, CA: Sage Publications, 1993.
48. Fleishman JA, Gebo KA, Reilly ED, Conviser R, Mathews C, Korthuis T, Hellinger J, Rutstein R, Keiser P, Rubin H, Moore RD, for the HIV Research Network. Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002. Med Care 2005; 43: III-40 to III-52.
49. Duggan MG, Evans WN. Estimating the impact of medical innovation: a case study of HIV antiretroviral treatments. Forum Health Econ Policy 2008; 11: 1-37.
50. Liu C, Ostrow D, Detels R, Hu Z, Johnson L, Kingsley L, Jacobson LP. Impacts of HIV infection and HAART on quality of life. Qual Life Res 2006; 15: 941-949.
51. Donald M, Dower J, Kavanagh D. (2005). Integrated versus non-integrated management and care for clients with co-occurring mental health and substance use disorders: A qualitative systematic review of randomized controlled trials. Soc Sci Med, 60: 1371-1383.
52. Ware JE Jr, Davies-Avery A, Steward AL. The measurement and meaning of patient satisfaction. Health Med Care Serv Rev 1970; 1: 3-15.
53. Ettner S, Conover C, Proescholdbell RJ, Weaver MR, Ang A, Arno P for the Cost Subcommittee of the HIV/AIDS Treatment Adherence, Health Outcomes and Cost Study. Triply-diagnosed patients in the HIV/AIDS Treatment Adherence, Health Outcomes and Cost Study: patterns of home care use. AIDS Care 2008; 20: 1177-89.
54. Sherbourne CD, Unutzer J, Schoenbaum M, Duan N, Lenert LA, Sturm R, Wells KB. Can utility-weighted health-related quality-of-life estimates capture health effects of quality improvement or depression? Med Care 2001; 39: 1246-1259.